Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metabolically armed anti-CD19 chimeric antigen receptor T cell therapy - Leman Biotech

Next Previous
X
Search
Drug Profile

Metabolically armed anti-CD19 chimeric antigen receptor T cell therapy - Leman Biotech

Alternative Names: Anti-CD19 chimeric antigen receptor T cell therapy - Leman Biotech; Meta10-19 - Leman Biotech

Latest Information Update: 07 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Leman Biotech
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 01 May 2024 The Children's Hospital of Zhejiang University School of Medicine and Leman Biotech initiates enrolment in a phase 0 trial for Precursor B-cell lymphoblastic leukaemia-lymphoma and Non-Hodgkin's lymphoma (Second-line therapy or greater) in China (IV) (NCT06393335)
  • 07 Nov 2023 He Huang in collaboration with Leman Biotech initiates the early phase I trial for r/r Diffuse large B-cell lymphoma (Second-line therapy or greater) in China (IV, Infusion) (NCT06120166)
  • 17 Feb 2023 Phase-I clinical trials in Precursor B-cell lymphoblastic leukaemia-lymphoma (Late-stage disease, Second-line therapy or greater) in China (IV) (NCT05747157)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top